<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Bio-techne Corp — News on 6ix</title>
<link>https://6ix.com/company/bio-techne-corp</link>
<description>Latest news and press releases for Bio-techne Corp on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 16 Apr 2026 12:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/bio-techne-corp" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835c80378dffbe2df11bb2c.webp</url>
<title>Bio-techne Corp</title>
<link>https://6ix.com/company/bio-techne-corp</link>
</image>
<item>
<title>Bio-Techne Introduces Streamlined Brand Architecture to Help Customers Navigate Solutions Faster and With Greater Clarity</title>
<link>https://6ix.com/company/bio-techne-corp/news/bio-techne-introduces-streamlined-brand-architecture-to-help-customers-navigate-solutions-faster-and-with-greater-clarity</link>
<guid isPermaLink="true">https://6ix.com/company/bio-techne-corp/news/bio-techne-introduces-streamlined-brand-architecture-to-help-customers-navigate-solutions-faster-and-with-greater-clarity</guid>
<pubDate>Thu, 16 Apr 2026 12:00:00 GMT</pubDate>
<description>Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science research tools, analytical instruments, and diagnostics, today announced a streamlined brand architecture designed to enable scientists and clinicians to more easily find the answers they need based on their application and stage of research.</description>
</item>
<item>
<title>Bio-Techne to Host Conference Call on May 6, 2026, to Announce Third Quarter Fiscal 2026 Financial Results</title>
<link>https://6ix.com/company/bio-techne-corp/news/bio-techne-to-host-conference-call-on-may-6-2026-to-announce-third-quarter-fiscal-2026-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/bio-techne-corp/news/bio-techne-to-host-conference-call-on-may-6-2026-to-announce-third-quarter-fiscal-2026-financial-results</guid>
<pubDate>Tue, 14 Apr 2026 04:00:00 GMT</pubDate>
<description>MINNEAPOLIS, April 14, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on</description>
</item>
<item>
<title>Bio-Techne Advances Spatial Biology with Modular Expansion of COMET™ Suite</title>
<link>https://6ix.com/company/bio-techne-corp/news/bio-techne-advances-spatial-biology-with-modular-expansion-of-comettm-suite</link>
<guid isPermaLink="true">https://6ix.com/company/bio-techne-corp/news/bio-techne-advances-spatial-biology-with-modular-expansion-of-comettm-suite</guid>
<pubDate>Wed, 25 Mar 2026 04:00:00 GMT</pubDate>
<description>New SPYRE™ Focus Panels (Stroma and Vessel) broaden modular panel options, enabling deeper targeted insights in spatial biology workflows. SPYRE™</description>
</item>
<item>
<title>Bio-Techne's Ella Platform Achieves CE-IVD Marking Expanding Access to Rapid, Cartridge‑Based Immunoassays for European Clinical Laboratories</title>
<link>https://6ix.com/company/bio-techne-corp/news/bio-technes-ella-platform-achieves-113000228</link>
<guid isPermaLink="true">https://6ix.com/company/bio-techne-corp/news/bio-technes-ella-platform-achieves-113000228</guid>
<pubDate>Mon, 16 Feb 2026 11:30:00 GMT</pubDate>
<description>Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents, and diagnostic products, today announced that the Ella benchtop immunoassay platform has received CE-IVD marking1 and is now available for sale in the European Union. This achievement brings Ella's hallmark ease of use, speed and reproducibility to clinical settings, helping laboratories streamline workflows and support timely decision-making.</description>
</item>
<item>
<title>Bio-Techne Announces Changes to its Leadership Team</title>
<link>https://6ix.com/company/bio-techne-corp/news/bio-techne-announces-changes-to-its-leadership-team</link>
<guid isPermaLink="true">https://6ix.com/company/bio-techne-corp/news/bio-techne-announces-changes-to-its-leadership-team</guid>
<pubDate>Wed, 11 Feb 2026 14:00:00 GMT</pubDate>
<description>Bio-Techne Corporation (NASDAQ: TECH) today announced that Dr. Matt McManus, President of Bio-Techne's Diagnostics and Spatial Biology Segment, will be transitioning from his role, effective March 1, 2026, and will remain with Bio-Techne for a period of time to support a smooth transition.</description>
</item>
<item>
<title>Bio-Techne Declares Dividend</title>
<link>https://6ix.com/company/bio-techne-corp/news/bio-techne-declares-dividend-113000702</link>
<guid isPermaLink="true">https://6ix.com/company/bio-techne-corp/news/bio-techne-declares-dividend-113000702</guid>
<pubDate>Wed, 04 Feb 2026 11:30:00 GMT</pubDate>
<description>Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended December 31, 2025. The quarterly dividend will be payable February 27, 2026, to all common shareholders of record on February 16, 2026. Future cash dividends will be considered by the Board of Directors on a quarterly basis.</description>
</item>
<item>
<title>Bio-Techne Releases Second Quarter Fiscal 2026 Results</title>
<link>https://6ix.com/company/bio-techne-corp/news/bio-techne-releases-second-quarter-113000453</link>
<guid isPermaLink="true">https://6ix.com/company/bio-techne-corp/news/bio-techne-releases-second-quarter-113000453</guid>
<pubDate>Wed, 04 Feb 2026 11:30:00 GMT</pubDate>
<description>Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the second quarter ending December 31, 2025.</description>
</item>
<item>
<title>Bio-Techne Expands 3D Stem Cell and Organoid Culture Portfolio with a Fully Defined Synthetic Alternative</title>
<link>https://6ix.com/company/bio-techne-corp/news/bio-techne-expands-3d-stem-113000214</link>
<guid isPermaLink="true">https://6ix.com/company/bio-techne-corp/news/bio-techne-expands-3d-stem-113000214</guid>
<pubDate>Mon, 02 Feb 2026 11:30:00 GMT</pubDate>
<description>Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents and diagnostic products, today announced the launch of Cultrex™ Synthetic Hydrogel,a fully defined synthetic extracellular matrix (ECM) designed to support reproducible and scalable 3D stem cell and organoid research. The new product expands Bio-Techne's established Cultrex ECM portfolio, offering researchers a synthetic alternative that reduces lot-to-lot variability while supporting translational and regul</description>
</item>
<item>
<title>Bio-Techne Launches Simple Plex Ultra-Sensitive Assays on Ella Platform to Enable Femtogram-Level Detection of Neurological Biomarkers</title>
<link>https://6ix.com/company/bio-techne-corp/news/bio-techne-launches-simple-plex-113000399</link>
<guid isPermaLink="true">https://6ix.com/company/bio-techne-corp/news/bio-techne-launches-simple-plex-113000399</guid>
<pubDate>Wed, 28 Jan 2026 11:30:00 GMT</pubDate>
<description>Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents, and diagnostic products, today announced the launch of Simple Plex Ultra-Sensitive Assays on the Ella automated benchtop platform.</description>
</item>
<item>
<title>Bio-Techne to Host Conference Call on February 4, 2026, to Announce Second Quarter Fiscal 2026 Financial Results</title>
<link>https://6ix.com/company/bio-techne-corp/news/bio-techne-host-conference-call-february-4-2026-announce-second-quarter-fiscal-2026</link>
<guid isPermaLink="true">https://6ix.com/company/bio-techne-corp/news/bio-techne-host-conference-call-february-4-2026-announce-second-quarter-fiscal-2026</guid>
<pubDate>Tue, 20 Jan 2026 05:00:00 GMT</pubDate>
<description>MINNEAPOLIS, Jan. 20, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on</description>
</item>
<item>
<title>Bio-Techne to Present at the 2026 J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/bio-techne-corp/news/bio-techne-present-2026-jp-morgan-healthcare-conference-2025-12-23</link>
<guid isPermaLink="true">https://6ix.com/company/bio-techne-corp/news/bio-techne-present-2026-jp-morgan-healthcare-conference-2025-12-23</guid>
<pubDate>Tue, 23 Dec 2025 05:00:00 GMT</pubDate>
<description>MINNEAPOLIS, Dec. 23, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman, President and Chief Executive Officer,</description>
</item>
<item>
<title>Bio-Techne Partners with the Wyss Center Geneva to Advance Automated 3D Multiomics Technology and Accelerate Spatial Biology</title>
<link>https://6ix.com/company/bio-techne-corp/news/bio-techne-partners-wyss-center-geneva-advance-automated-3d-multiomics-technology-and</link>
<guid isPermaLink="true">https://6ix.com/company/bio-techne-corp/news/bio-techne-partners-wyss-center-geneva-advance-automated-3d-multiomics-technology-and</guid>
<pubDate>Thu, 11 Dec 2025 05:00:00 GMT</pubDate>
<description>Collaboration aims to automate RNA and protein detection in 3D tissue specimens, reducing complexity and technical barriers.Innovation has the potential to</description>
</item>
<item>
<title>Bio-Techne Launches the Enhanced Leo™ System Delivering Advanced Multiplexing and High-Throughput Protein Analysis</title>
<link>https://6ix.com/company/bio-techne-corp/news/bio-techne-launches-enhanced-leotm-system-delivering-advanced-multiplexing-and-high</link>
<guid isPermaLink="true">https://6ix.com/company/bio-techne-corp/news/bio-techne-launches-enhanced-leotm-system-delivering-advanced-multiplexing-and-high</guid>
<pubDate>Tue, 09 Dec 2025 05:00:00 GMT</pubDate>
<description>Combines chemiluminescence detection with dual-channel fluorescence in the near-infrared and infrared (NIR and IR) ranges for expanded multiplexingEnables up</description>
</item>
<item>
<title>Bio-Techne to Present at Upcoming Investor Conferences</title>
<link>https://6ix.com/company/bio-techne-corp/news/bio-techne-present-upcoming-investor-conferences-2025-11-25</link>
<guid isPermaLink="true">https://6ix.com/company/bio-techne-corp/news/bio-techne-present-upcoming-investor-conferences-2025-11-25</guid>
<pubDate>Tue, 25 Nov 2025 05:00:00 GMT</pubDate>
<description>MINNEAPOLIS, Nov. 25, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it will present at the following investor</description>
</item>
<item>
<title>Bio-Techne Licenses AI-Designed NovoBody™ Duo Molecules from Monod Bio to Expand Recombinant Protein Portfolio</title>
<link>https://6ix.com/company/bio-techne-corp/news/bio-techne-licenses-ai-designed-novobodytm-duo-molecules-monod-bio-expand-recombinant</link>
<guid isPermaLink="true">https://6ix.com/company/bio-techne-corp/news/bio-techne-licenses-ai-designed-novobodytm-duo-molecules-monod-bio-expand-recombinant</guid>
<pubDate>Tue, 18 Nov 2025 05:00:00 GMT</pubDate>
<description>Partnership strengthens Bio-Techne's leadership in AI-enabled protein innovation NovoBody™ Duo molecules offer multi-specific binding capabilities for</description>
</item>
<item>
<title>BIO-TECHNE DECLARES DIVIDEND</title>
<link>https://6ix.com/company/bio-techne-corp/news/bio-techne-declares-dividend-2025-11-05</link>
<guid isPermaLink="true">https://6ix.com/company/bio-techne-corp/news/bio-techne-declares-dividend-2025-11-05</guid>
<pubDate>Wed, 05 Nov 2025 05:00:00 GMT</pubDate>
<description>MINNEAPOLIS, Nov. 5, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08</description>
</item>
<item>
<title>Bio-Techne Releases First Quarter Fiscal 2026 Results</title>
<link>https://6ix.com/company/bio-techne-corp/news/bio-techne-releases-first-quarter-fiscal-2026-results-2025-11-05</link>
<guid isPermaLink="true">https://6ix.com/company/bio-techne-corp/news/bio-techne-releases-first-quarter-fiscal-2026-results-2025-11-05</guid>
<pubDate>Wed, 05 Nov 2025 05:00:00 GMT</pubDate>
<description>MINNEAPOLIS, Nov. 5, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the first quarter ended September</description>
</item>
<item>
<title>AI-Powered Spatial Biology Workflow from Bio-Techne and Nucleai Enables Predictive Biomarker Discovery in Melanoma Patients</title>
<link>https://6ix.com/company/bio-techne-corp/news/ai-powered-spatial-biology-workflow-bio-techne-and-nucleai-enables-predictive</link>
<guid isPermaLink="true">https://6ix.com/company/bio-techne-corp/news/ai-powered-spatial-biology-workflow-bio-techne-and-nucleai-enables-predictive</guid>
<pubDate>Tue, 04 Nov 2025 05:00:00 GMT</pubDate>
<description>Clinical trial data demonstrates how Bio-Techne's spatial biology technology and Nucleai's AI-powered multimodal platforms can identify predictive biomarkers</description>
</item>
<item>
<title>ScaleReady Announces a G-Rex® Grant has been awarded to Sonoma Biotherapeutics</title>
<link>https://6ix.com/company/bio-techne-corp/news/scaleready-announces-a-g-rexr-grant-has-been-awarded-to-sonoma-biotherapeutics</link>
<guid isPermaLink="true">https://6ix.com/company/bio-techne-corp/news/scaleready-announces-a-g-rexr-grant-has-been-awarded-to-sonoma-biotherapeutics</guid>
<pubDate>Mon, 03 Nov 2025 12:00:00 GMT</pubDate>
<description>ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation and CellReady, today announced that Sonoma Biotherapeutics has been awarded a $300,000 G-Rex® Grant. SonomaBio's G-Rex® Grant will enable expeditious development of a G-Rex® based manufacturing process to produce gene-modified regulatory T cell (Treg) therapies for clinical investigation of SonomaBio products in development for various autoimmune related disorders.</description>
</item>
<item>
<title>Bio-Techne Launches ProximityScope™ Assay on the BOND RX platform from Leica Biosystems to Advance Spatial Protein-Protein Interactions Research</title>
<link>https://6ix.com/company/bio-techne-corp/news/bio-techne-launches-proximityscopetm-assay-bond-rx-platform-leica-biosystems-advance</link>
<guid isPermaLink="true">https://6ix.com/company/bio-techne-corp/news/bio-techne-launches-proximityscopetm-assay-bond-rx-platform-leica-biosystems-advance</guid>
<pubDate>Tue, 28 Oct 2025 04:00:00 GMT</pubDate>
<description>Visualizes functional protein-protein interactions directly within fixed tissue at subcellular resolution Enables simultaneous detection of protein</description>
</item>
</channel>
</rss>